HAEi Global Access Program for RUCONEST® Now Live
Summary
“We are extremely proud to have established HAEi GAP with our current partners and to be able to announce that, from today, physicians are able to request RUCONEST to meet the needs of their patients.” Simon Estcourt, Managing Director, Managed Access, Clinigen Group said: “We are very pleased to work with Pharming to help HAEi realize their mission to ensure that sufferers of hereditary angioedema worldwide can access this effective and potentially life-saving treatment.HAE is caused by a deficiency of the C1 esterase inhibitor protein, which is present in blood and helps control inflammation (swelling) and parts of the immune system.Almost all HAE patients suffer from bouts of severe abdominal pain, nausea, vomiting and diarrhea caused by swelling of the intestinal wall.Edema of the throat, nose or tongue is particularly dangerous and potentially life-threatening and can lead to obstruction of the airway passages.HAE is caused by a deficiency of the C1 esterase inhibitor protein, which is present in blood and helps control inflammation (swelling) and parts of the immune system.Our Managed Access business provides early access to unlicensed investigational medicines on behalf of pharmaceutical companies.For more information, please visit www.clinigengroup.com Contact Information Instinctif Partners (Clinigen media relations) Melanie Toyne-Sewell/Jen Lewis/Emma Barlow +44 (0) 20 7457 2020 clinigengroup.com Click here to view the list of recent Press Releases from Clinigen Group Promote Your Business Press Release Pricing Email this page to a friend